These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC). McCarthy F; Roshani R; Steele J; Hagemann T J Leukoc Biol; 2013 Dec; 94(6):1201-6. PubMed ID: 23695306 [TBL] [Abstract][Full Text] [Related]
6. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction. Socinski MA Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469 [No Abstract] [Full Text] [Related]
7. To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis. Khunger M; Calabrese C; Kontzias A; Velcheti V J Thorac Oncol; 2017 Sep; 12(9):e147-e149. PubMed ID: 28838717 [No Abstract] [Full Text] [Related]
8. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. Santana-Davila R; Chow LQ Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785 [No Abstract] [Full Text] [Related]
9. Immunogenic targets in non-small cell lung cancer: more is more. Gnjatic S Clin Cancer Res; 2005 Aug; 11(15):5331-2. PubMed ID: 16061843 [No Abstract] [Full Text] [Related]
10. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Kakimi K; Nakajima J; Wada H Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127 [TBL] [Abstract][Full Text] [Related]
14. A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials. Shaikh SS; Kumthekar PU; Mohindra NA J Neurooncol; 2019 Aug; 144(1):235-237. PubMed ID: 31240523 [No Abstract] [Full Text] [Related]
15. New strategies in lung cancer: translating immunotherapy into clinical practice. Forde PM; Kelly RJ; Brahmer JR Clin Cancer Res; 2014 Mar; 20(5):1067-73. PubMed ID: 24470514 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? Rolfo C; Sortino G; Smits E; Passiglia F; Bronte G; Castiglia M; Russo A; Santos ES; Janssens A; Pauwels P; Raez L Expert Rev Anticancer Ther; 2014 Oct; 14(10):1173-87. PubMed ID: 25148289 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Van den Heuvel MM; Burgers SA; van Zandwijk N Clin Lung Cancer; 2009 Mar; 10(2):99-105. PubMed ID: 19362952 [TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]. Shepherd FA; Douillard JY; Blumenschein GR Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):C9-20. PubMed ID: 23601304 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? Waqar SN; Morgensztern D Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]